• Atara Biotherapeutics Inc ATRA.OQ reported a quarterly adjusted loss of $2.93​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of $-16.50. The mean expectation of six analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-4.67 to 5 cents per share.

• Revenue rose 1,779.8% to $40.19 million from a year ago; analysts expected $35.17 million.

• Atara Biotherapeutics Inc's reported EPS for the quarter was a loss of $2.93​.

• The company reported a quarterly loss of $21.91 million.

• Atara Biotherapeutics Inc shares had risen by 44.8% this quarter and lost 8.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 31.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Atara Biotherapeutics Inc is 10.00

This summary was machine generated from LSEG data November 12 at 11:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)